WILEX
Ladenburg
About WILEX
WILEX a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II substance for the treatment of pancreatic and breast cancer. The company's products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $65.5M
- Funding stage: IPO
- Last round: Post-IPO Debt (Mar 2010)
- Ticker: etr:WL6
- Website: wilex.de
- Phone: + 49 6203 1009 0
Industries & Categories
Biopharma, Biotechnology, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/wilex-1703891 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.